Oruka Therapeutics, Inc.
Clinical trials sponsored by Oruka Therapeutics, Inc., explained in plain language.
-
New psoriasis drug shows promise in Mid-Stage trial
Disease control Recruiting nowThis study tests a new medicine called ORKA-001 for adults with moderate-to-severe plaque psoriasis, a skin condition causing red, scaly patches. About 160 participants will receive either the drug or a placebo to see if it can completely clear the skin by week 16. The goal is to…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New psoriasis drug ORKA-001 tested for Long-Term safety
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a drug called ORKA-001 for people with moderate-to-severe plaque psoriasis. It is an open-label extension, meaning everyone gets the drug, and it includes 240 adults who already completed a previous trial with ORKA-0…
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New psoriasis drug shows promise in Mid-Stage trial
Symptom relief Recruiting nowThis study tests a new medicine called ORKA-002 for adults with moderate-to-severe plaque psoriasis. About 160 participants will receive either the drug or a placebo to see if it clears skin and is safe. The goal is to find the best dose and check for side effects over 16 weeks.
Phase: PHASE2 • Sponsor: Oruka Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC